The initial step in human immunodeficiency virus type 1 gagpropol processing can be regulated by reversible oxidation

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Daniels, Sarah I ^a   Davis, David A ^a   Soule, Erin E ^a   Stahl, Stephen J ^b   Tebbs, Irene R ^a   Wingfield, Paul ^b   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTEINE; DIAMIDE; DITHIOTHREITOL; GAGPROPOL PROTEIN; POLYPROTEIN; PROTEINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; ASSAY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; OXIDATION; PLASMID; PROTEIN PROCESSING; RETROVIRUS; METABOLISM; OXIDATION REDUCTION REACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

HIV-1; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRAL PROTEINS;

EID: 78149463288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013595     Document Type: Article

References (35)

1. Coffin JM, Hughes SH, Vatmus HE, eds (1997) Retroviruses. New York: Cold Spring Harbor. 843 p.
2. Peng C, Ho BK, Chang TW, Chang NT (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. Journal of virology 63(6): 2550-2556.
3. Gottlinger HG, Sodroski JG, Haseltine WA (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America 86(15): 5781-5785.
4. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B (1993) Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of viruslike particles. Virology 193(2): 661-671.
5. Krausslich H-G (1991) Human Immunodeficiency Virus Proteinase Dimer as Component of the Viral Polyprotein Prevents Particle Assembly and Viral Infectivity. Proceddings of the National Acadamy of Sciences 88: 3213-3217.
6. Burstein H, Bizub D, Skalka AM (1991) Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. Journal of virology 65(11): 6165-6172.
7. Davis DA, Yusa K, Gillim LA, Newcomb FM, Mitsuya H, et al. (1999) Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. Journal of virology 73(2): 1156-1164.
8. Davis DA, Brown CA, Newcomb FM, Boja ES, Fales HM, et al. (2003) Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation. Journal of virology 77(5): 3319-3325.
9. Davis DA, Tebbs IR, Daniels SI, Stahl SJ, Kaufman JD, et al. (2009) Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach. The Biochemical journal 419(2): 497-506.
10. Parker SD, Hunter E (2001) Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro. Proceedings of the National Academy of Sciences of the United States of America 98(25): 14631-14636.
11. Davis DA, Newcomb FM, Starke DW, Ott DE, Mieyal JM, et al. (1997) Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. Journal of Biological Chemistry 272(41): 25935-25940.
12. Davis DA, Newcomb FM, Moskovitz J, Fales HM, Levine RL, et al. (2002) Reversible Oxidation of HIV-2 Protease. In: Sies H, Packer L, eds. Methods in Enzymology. New York: Academic Press. pp 249-259.
13. Pettit SC, Gulnik S, Everitt L, Kaplan AH (2003) The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. Journal of virology 77(1): 366-374.
14. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH (2004) Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. Journal of virology 78(16): 8477-8485.
15. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, et al. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. Journal of virology 72(4): 2846-2854.
16. Pettit CS, Simsic J, Loeb DD, Everitt L, Hutchison III CA, et al. (1991) Analysis of Retroviral protease Cleavage Sites Reveals Two Types of Cleavage Sites and the Structural requirements of the P1 Amino Acid. The Journal of biological chemistry 266(22): 14539-14547.
17. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, et al. (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. Journal of virology 68(12): 8017-8027.
18. Richards AD, Phylip LH, Farmerie WG, Scarborough PE, Alvarez A, et al. (1990) Sensitive, soluble chromogenic substrates for HIV-1 proteinase. The Journal of biological chemistry 265(14): 7733-7736.
19. Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH (2005) Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. Journal of virology 79(16): 10601-10607.
20. Davis DA, Dorsey K, Wingfield PT, Stahl SJ, Kaufman J, et al. (1996) Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 35(7): 2482-2488.
21. Kosower EM, Kosower NS (1969) Lest I forget thee, glutathione. Nature 224(5215): 117-120.
22. Schuppe I, Moldeus P, Cotgreave IA (1992) Protein-specific S-thiolation in human endothelial cells during oxidative stress. Biochemical pharmacology 44(9): 1757-1764.
23. Davis DA, Newcomb FM, Moskovitz J, Wingfield PT, Stahl SJ, et al. (2000) HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. The Biochemical journal 346: 305-311.
24. Turpin JA, Terpening SJ, Schaeffer CA, Yu G, Glover CJ, et al. (1996) Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. Journal of virology 70(9): 6180-6189.
25. Kuiken CL, Foley B, Hahn B, Korber B, McCutchan F, et al. (2004) HIV Sequence Compendium 2004. Los Alamos National Laboratory. Los AlamosNM: Theoretical Biology and Biophysics Group.
26. Ciriolo MR, Palamara AT, Incerpi S, Lafavia E, Bue MC, et al. (1997) Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection. The Journal of biological chemistry 272(5): 2700-2708.
27. Kurata S (1996) Sensitization of the HIV-1-LTR upon long term low dose oxidative stress. The Journal of biological chemistry 271(36): 21798-21802.
28. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, et al. (1995) Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses 11(9): 1049-1061.
29. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, et al. (1995) HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. The EMBO journal 14(3): 546-554.
30. Aukrust P, Svardal AM, Muller F, Lunden B, Berge RK, et al. (1995) Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 86(1): 258-267.
31. Koh Y, Matsumi S, Das D, Amano M, Davis DA, et al. (2007) Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. The Journal of biological chemistry 282(39): 28709-28720.
32. Darke PL, Jordan SP, Hall DL, Zugay JA, Shafer JA, et al. (1994) Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates. Biochemistry 33(1): 98-105.
33. Mascolini M, Richman D, Larder B, Mellors J, Boucher CA (2008) Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations. Antiviral therapy 13(2): 319-334.
34. Scharf SJ, Horn GT, Erlich HA (1986) Direct cloning and sequence analysis of enzymatically amplified genomic sequences. Science, (New York, NY), 233(4768): 1076-1078.
35. Davis DA, Brown CA, Singer KE, Wang V, Kaufman J, et al. (2006) Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. Antiviral Res 72(2): 89-99.